Targeted Inhibition of Aneurysm Expansion and Vascular Calcification via Oxidation-Sensitive Polymer Delivery

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Science Advances  https://doi.org/10.1126/sciadv.adz3713 
Dr. Wanling Liu  et al.

Points

Researchers engineered an oxidation-sensitive polymer shell to encapsulate ultrasmall Prussian blue nanoparticles that target inflammatory sites associated with abdominal aortic aneurysms.
The nanozyme releases its cargo in response to high levels of reactive oxygen species to suppress oxidative stress and prevent vascular smooth muscle cell apoptosis.
Animal models demonstrated that this targeted antioxidant approach significantly inhibited aneurysm expansion and outperformed standard cardiovascular medications like clopidogrel in long-term efficacy.
The ultrasmall size of the active particles allows for renal clearance and subsequent detection in urine to provide a noninvasive method for monitoring treatment progress.
This theranostic platform establishes a clinical feedback loop where declining urinary signals correlate with pathological improvement and help determine the optimal duration of therapy.

Summary

This study introduces OZn, a reactive oxygen species (ROS)-responsive theranostic nanozyme designed for the targeted treatment and noninvasive monitoring of abdominal aortic aneurysm (AAA). Recognizing that oxidative stress drives AAA progression through vascular smooth muscle cell apoptosis and matrix degradation, researchers engineered the platform by encapsulating ultrasmall Prussian blue analog nanoparticles (SPBZn) within an oxidation-sensitive dextran shell. Upon intravenous administration, the construct passively targets inflammatory aneurysmal lesions, where the local high-ROS microenvironment triggers shell degradation and payload release.

In CaCl2-induced rat models, OZn demonstrated potent superoxide dismutase– and catalase–like enzymatic activities. The treatment effectively suppressed oxidative stress, mitigated pathological calcification, and preserved elastin fibers, thereby inhibiting aneurysm expansion. Notably, efficacy assessments indicated that the nanozyme outperformed clopidogrel in long-term models, substantially reducing vascular smooth muscle cell apoptosis and macrophage-associated inflammation without the systemic side effects often associated with standard pharmacological interventions.

The system utilizes a renal-clearable feedback mechanism for real-time disease monitoring. Following therapeutic action, the ultrasmall SPBZn particles are excreted via urine, where their catalytic activity serves as a quantifiable biomarker. The study observed that urinary signals correlated directly with pathological status; a gradual decline in signal aligned with histological improvements, effectively guiding treatment duration. This establishes a closed-loop theranostic strategy, integrating targeted antioxidant therapy with noninvasive urinalysis to manage AAA progression and evaluate therapeutic response.

Link to the article: https://www.science.org/doi/10.1126/sciadv.adz3713

References

Liu, W., Zhang, Y., Cui, X., Sun, Q., Gu, X., Li, T., He, S., Qin, Z., & Wei, H. (2025). An ultrasmall theranostic nanozyme for abdominal aortic aneurysm management and therapeutic efficacy monitoring. Science Advances, 11(49), eadz3713. https://doi.org/10.1126/sciadv.adz3713